PhD Scientific Days 2026

Poster Session 3.J - Theoretical and Translational Medicine

Evaluation of mEHT Efficacy in CT26 and MC38 Murine Tumor Models Using a New Cooling System (25°C)

Name of the presenter

Al-murshidy, Hakim Bahlok Jebur

Institute/workplace of the presenter

Clinical pathophysiology

Authors

Hakim Bahlok Jebur Al-murshidy¹, Qusay O. Abdalla², Eslam Abdalalem², Mohamed I. Elsalahaty², Dániel Bócsi², Mingming He², Ebsa Tofik Ahmed², Yibo Gu², Zoltán Koós², Csaba András Schvarcz², Hamar Péter²
1: Semmelweis University, Institute of clinical pathophysiology, 1094 Budapest, Tűzoltó u. 37-47.
2: Semmelweis University,Institute of clinical pathophysiology, 1094 Budapest, Tűzoltó u. 37-47.

Text of the abstract

Introduction: Colorectal cancer remains a major cause of cancer-related morbidity and mortality, and new local treatment strategies are needed.
Modulated electrohyperthermia (mEHT) is a non-invasive thermal approach designed to selectively target tumor tissue.
Its therapeutic effect may depend on tumor biology and the tumor microenvironment.
Therefore, evaluating mEHT in different colorectal tumor models is important to define its efficacy and consistency.
Aim: To evaluate the anti-tumor efficacy of mEHT in CT26 and MC38 murine colorectal cancer models using a new cooling system at 25°C.
Methods: Female BALB/c mice were subcutaneously inoculated with CT26 cells in the flank, whereas MC38 cells were subcutaneously implanted into the flank of C57BL/6 mice. Tumor growth was monitored by using digital caliper and ultrasound imaging (Phillips Sonos 5500). Animals were randomized into sham and mEHT treated groups: CT26 (n=12), and MC38 (n=12). Treated groups received 4 sessions of 30-minute treatment every 48 hours using Labehy 200 (Oncotherm Ltd.). Tumors were harvested 24 hours after the fourth treatment session, then weighed and processed for further analyses.
Result: mEHT significantly reduced tumor volume in both CT26 and MC38 models compared with sham controls (CT26: p = 0.0110; MC38: p = 0.0132). Tumor weight was also significantly decreased in both models (CT26: p = 0.0146; MC38: p = 0.0039).
No significant changes in body weight were observed, suggesting good tolerability of the treatment. Analysis of the tumor destruction ratio is ongoing.
Conclusion: mEHT demonstrated consistent anti-tumor efficacy in both colorectal cancer models without evidence of systemic toxicity. These findings support further exploration of mEHT-based combination strategies, particularly with cell cycle–targeting therapies such as cyclin-dependent kinase (CDK) inhibitors. Future studies will focus on evaluating this combination.
Funding: NKFIH OTKA (OTKA_K 145998), SE250-2026-119